News >

FDA Grants Frontline Alectinib Priority Review for ALK-Positive NSCLC

Jason Harris
Published: Thursday, Aug 03, 2017

Dr. Sandra Horning
Sandra Horning, MD
The FDA has granted a priority review to a supplemental new drug application (sNDA) for alectinib (Alecensa) for the frontline treatment of patients with ALK-positive locally advanced or metastatic non–small cell lung cancer (NSCLC), according to Genentech (Roche), the manufacturer of the second-generation ALK inhibitor.

-positive NSCLC.
FDA grants Genentech’s Alecensa priority review for initial treatment of people with ALK-positive lung cancer. Genentech. Available at: http://bit.ly/2u67edG. Accessed August 3, 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x